Eli Lilly COVID Antibody Treatment Gets Emergency FDA Authorization

Eli Lilly COVID Antibody Treatment Gets Emergency FDA Authorization Brian Wang | November 10, 2020 | U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Eli Lilly & Companies investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive…Continue Reading

U.S. agrees to pay Eli Lilly $375 million for 300,000 doses of coronavirus antibody drug

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, September 17, 2020.Mike Blake | ReutersThe U.S. government will pay Eli Lilly $375 million to supply 300,00 doses of its experimental antibody drug to treat the coronavirus, the company announced Wednesday.The agreement is for delivery over the two months…Continue Reading

Lilly Stops Antibody Trial in Hospitalized COVID-19 Patients

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Eli Lilly announced it will halt its ACTIV-3 trial evaluating the antibody bamlanivimab in combination with remdesivir for people hospitalized with COVID-19, after new evidence regarding efficacy emerged. The new data from the National Institutes of Health suggest that the experimental…Continue Reading

Lilly antibody drug fails in a COVID-19 study; others go on

MARILYNN MARCHIONE, AP Chief Medical WriterOct. 26, 2020Updated: Oct. 26, 2020 6:52 p.m.U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t seem to be helping them. Independent monitors had paused enrollment in the study two weeks ago because of a possible…Continue Reading